Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2063844
Abstract: ABSTRACT Introduction Since the advent of anti-HER2 therapies, evidence surrounding adjuvant treatment of small (T1mic, T1a, and T1b), node-negative, HER2-positive breast cancer (HER2+ BC) has remained limited. Practices vary widely between institutions with little known… read more here.
Keywords: negative her2; node negative; t1mic t1a; her2 ... See more keywords
Abstract P5-05-20: Efficacy of Fam-Trastuzumab Deruxtecan-nxki (T-DXd) in Hormone Receptor-Negative, HER2-3+ Metastatic Breast Cancer: A Case Study
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p5-05-20
Abstract: This case report evaluates the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd) in a 59-year-old woman with hormone receptor-negative, HER2-3+ breast cancer. Following initial treatment with the TCHP chemotherapy regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab), the patient… read more here.
Keywords: cancer; breast cancer; dxd; breast ... See more keywords
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e12613
Abstract: e12613 Background: The chemotherapy-free neoadjuvant regimens of dual HER2 blockade has showed encouraging rates of pathological complete response (pCR) in patients with HER2-positive breast cancer. Additionally, combining cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with… read more here.
Keywords: her2; her2 positive; breast cancer; negative her2 ... See more keywords